CoChat

Chronotherapy With Once-Daily Osilodrostat Improves Cortisol Rhythm, Quality of Life, and Sleep in Cushing's Syndrome

Open access

The DOI matches its Crossref record; 70 of the 71 references it cites were found in a registry or an index.

Abstract

Context: Medical therapy for Cushing syndrome (CS) typically aims to reduce daily cortisol output without addressing circadian rhythm restoration. No licensed drugs target this goal. Objective: We investigated the efficacy and safety of timed, once-daily osilodrostat administration in improving circadian cortisol profiles in CS. Methods: A prospective, multicenter study evaluated patients with well-controlled CS on a stable twice-daily osilodrostat therapy before and 60 to 90 days after transitioning to a single equivalent daily dose at 19:00 ± 1 hour. Circadian steroid analysis was performed on saliva, serum, and urine using ultra-high performance liquid chromatography–tandem mass spectrometry. Additional assessments included cardio-metabolic markers, quality of life, sleep function, and safety outcomes. Results: Sixteen patients (4 males; 7 pituitary, mean age 53.3 ± 11.8 years) were enrolled. At baseline, CS was well-controlled with a mean osilodrostat dose of 4.2 ± 1.3 mg. After transitioning, salivary cortisol exposure decreased significantly during the afternoon to early morning period (AUC16:00-08:00: −6.1 [−0.15 to −12.1] ng/mL/h, P = .029). Quality of life and sleep improved (CushingQoL: +4.2, P = .029; Pittsburgh Sleep Quality Index: −1.7, P = .049). Serum steroid precursors, including 11-deoxycorticosterone (−3.1 ng/mL/h, P = .008) and 11-deoxycortisol (−17.8 ng/mL/h, P = .005), decreased. Eight patients advancing dosing to 16:00 ± 1 hour showed comparable reductions, with phase shifts in acrophase and nadir. No patients developed adrenal insufficiency, liver toxicity, electrocardiogram abnormalities, or loss of disease control. Conclusion: Once-daily osilodrostat effectively and safely treats patients with biochemically controlled CS, improving circadian cortisol profiles, quality of life, and sleep. Findings support further exploration of chronotherapy-based approaches in CS management.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1210/clinem/dgaf206

Cites

70 of 70 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1. Salivary cortisol curves before and after shifting to once-daily osilodrostat administration. Comparison of TBID and TOD regimens. Data are mean ± SD.
Figure 1. Salivary cortisol curves before and after shifting to once-daily osilodrostat administration. Comparison of TBID and TOD regimens. Data are mean ± SD.CC BY · PubMed Central
Figure 2. Change in the exposure to cortisone and cortisone in afternoon through early morning (1600-0800 and 1600-0400) measured as estimated AUC of the daily cosinor-based salivary analysis. Data are mean ± SD.
Figure 2. Change in the exposure to cortisone and cortisone in afternoon through early morning (1600-0800 and 1600-0400) measured as estimated AUC of the daily cosinor-based salivary analysis. Data are mean ± SD.CC BY · PubMed Central
Figure 3. Change in serum steroid day curves and overall exposure (AUC8-20) across TBID and TOD. Data are mean ± standard error of the mean.
Figure 3. Change in serum steroid day curves and overall exposure (AUC8-20) across TBID and TOD. Data are mean ± standard error of the mean.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 70 references

Cited by

See all 28

Metadata

Authors
Ferrari, D., Bonaventura, I., Simeoli, C., Tomaselli, A., Vincenzi, L., De Alcubierre, D., Sciarra, F., Rizzo, F., Cerroni, L., Di Paola, N., Minnetti, M., Sbardella, E., Venneri, M. A., Pofi, R., Pivonello, R., Gianfrilli, D., Hasenmajer, V., & Isidori, A. M.
Affiliations
  • Sapienza University of Rome (IT)
  • University of Naples Federico II (IT)
  • Department of Experimental Medicine, “Sapienza” University of Rome , Rome 00161 ,
  • Dipartimento di Medicina Clinica e Chirurgia, Sezione di Endocrinologia, Diabetologia, Andrologia e Nutrizione, Università Federico II di Napoli , Naples 80131 ,
  • Churchill Hospital (GB)
  • Policlinico Umberto I (IT)
Corresponding author
Isidori, Andrea M
Venue
The Journal of Clinical Endocrinology & Metabolism
Published
2025-04-02
Volume
110
Issue
12
Pages
3525-3537
ISSN
  • 0021-972X (ISSN-L)
  • 1945-7197
OpenAlex
W4409093251
Cited by
28
References
71
Citations by year
2026: 15 · 2025: 13
FWCI
19.10
Type
journal article
Language
en
Open access
Locations
  • The Journal of Clinical Endocrinology & Metabolism (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
Funders
  • European Union—NextGenerationEU
  • Italian Ministry of University and Research (PNRR - M4C2-I1.3)
  • CUP (B53C22004000006)
  • Ministerial Research Project (PRIN PNRR Prot. P2022EA9RR_001)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pituitary Gland Disorders and Treatments
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
  • Health Sciences › Medicine › Surgery › Adrenal and Paraganglionic Tumors
Keywords
Cushing's syndrome, osilodrostat, chronotherapy, once-daily dosing, diurnal cortisol rhythm, salivary cortisol, quality of life, sleep quality, deoxycorticosterone, 11-deoxycortisol, adrenal insufficiency, pituitary Cushing's disease, timing of drug administration
MeSH terms
Adult, Aged, Circadian Rhythm, Cushing Syndrome, Female, Humans, Hydrocortisone, Imidazoles, Male, Middle Aged, Prospective Studies, Pyridines, Quality of Life, Saliva, Sleep, Treatment Outcome, Chronotherapy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Chronotherapy With Once-Daily Osilodrostat Improves Cortisol Rhythm, Quality of Life, and Sleep in Cushing's Syndrome. https://app.cochat.ai/papers/10.1210/clinem/dgaf206
The paper
Ferrari, D., Bonaventura, I., Simeoli, C., Tomaselli, A., Vincenzi, L., De Alcubierre, D., Sciarra, F., Rizzo, F., Cerroni, L., Di Paola, N., Minnetti, M., Sbardella, E., Venneri, M. A., Pofi, R., Pivonello, R., Gianfrilli, D., Hasenmajer, V., & Isidori, A. M. (2025). Chronotherapy With Once-Daily Osilodrostat Improves Cortisol Rhythm, Quality of Life, and Sleep in Cushing's Syndrome. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/clinem/dgaf206

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.